Analyst Price Targets — SOPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 10:09 am | Mark Massaro | BTIG | $9.00 | $6.84 | TheFly | Sophia Genetics price target raised to $9 from $8 at BTIG |
| August 5, 2026 10:00 am | Swayampakula Ramakanth | H.C. Wainwright | $14.00 | $6.84 | TheFly | Sophia Genetics price target raised to $14 from $12 at H.C. Wainwright |
| July 20, 2026 10:02 am | — | H.C. Wainwright | $12.00 | $5.87 | TheFly | Sophia Genetics initiated with a Buy at H.C. Wainwright |
| April 15, 2026 10:36 am | — | BTIG | $8.00 | $4.96 | TheFly | Sophia Genetics price target raised to $8 from $7 at BTIG |
| March 3, 2026 7:23 pm | Mark Massaro | BTIG | $7.00 | $4.10 | StreetInsider | BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH) |
| January 26, 2026 2:36 pm | — | Guggenheim | $7.00 | $5.35 | TheFly | Sophia Genetics price target raised to $7 from $6 at Guggenheim |
| March 6, 2025 12:11 pm | — | BTIG | $5.00 | $3.11 | TheFly | Sophia Genetics price target lowered to $5 from $6 at BTIG |
| August 7, 2024 11:35 am | Tejas Savant | Morgan Stanley | $5.00 | $3.92 | TheFly | Sophia Genetics downgraded to Equal Weight from Overweight at Morgan Stanley |
| June 27, 2024 6:20 am | Subbu Nambi | Guggenheim | $6.00 | $4.52 | StreetInsider | Guggenheim Starts Sophia Genetics SA (SOPH) at Buy |
| January 3, 2023 7:14 am | Mark Massaro | BTIG | $6.00 | $2.06 | TheFly | Sophia Genetics initiated with a Buy at BTIG |
Latest News for SOPH
The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That's because volume can provide an important measure of the conviction behind a stock's price movement.
SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares trading hands. The stock had previously closed at $8.65. Analyst Ratings Changes SOPH has been the subject of a
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements.
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue was $23.3 million, up 27% year-over-year Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis, compared to 67.0% reported and 74.4%…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SOPH.
U.S. House Trading
No House trades found for SOPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.